Critical Survey: Actinium Pharmaceuticals (NYSE:ATNM) vs. Leap Therapeutics (NASDAQ:LPTX)

Leap Therapeutics (NASDAQ:LPTX) and Actinium Pharmaceuticals (NYSE:ATNM) are both small-cap manufacturing companies, but which is the better investment? We will contrast the two companies based on the strength of their analyst recommendations, earnings, institutional ownership, profitability, valuation, dividends and risk.

Institutional and Insider Ownership

30.5% of Leap Therapeutics shares are owned by institutional investors. Comparatively, 27.5% of Actinium Pharmaceuticals shares are owned by institutional investors. 4.3% of Leap Therapeutics shares are owned by insiders. Comparatively, 0.6% of Actinium Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Analyst Ratings

This is a summary of current ratings and target prices for Leap Therapeutics and Actinium Pharmaceuticals, as reported by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Leap Therapeutics	1	0	0	0	1.00
Actinium Pharmaceuticals	0	0	1	0	3.00

Actinium Pharmaceuticals has a consensus price target of $4.00, suggesting a potential upside of 212.50%. Given Actinium Pharmaceuticals’ stronger consensus rating and higher possible upside, analysts plainly believe Actinium Pharmaceuticals is more favorable than Leap Therapeutics.

Risk and Volatility

Leap Therapeutics has a beta of -0.06, suggesting that its share price is 106% less volatile than the S&P 500. Comparatively, Actinium Pharmaceuticals has a beta of -0.3, suggesting that its share price is 130% less volatile than the S&P 500.

Earnings & Valuation

This table compares Leap Therapeutics and Actinium Pharmaceuticals”s top-line revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Leap Therapeutics	N/A	N/A	-$67.56 million	($1.22)	-1.68
Actinium Pharmaceuticals	$90,000.00	443.68	-$48.82 million	($1.10)	-1.16

Actinium Pharmaceuticals has higher revenue and earnings than Leap Therapeutics. Leap Therapeutics is trading at a lower price-to-earnings ratio than Actinium Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares Leap Therapeutics and Actinium Pharmaceuticals’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Leap Therapeutics	N/A	-247.44%	-146.51%
Actinium Pharmaceuticals	N/A	-100.85%	-47.89%

Summary

Actinium Pharmaceuticals beats Leap Therapeutics on 9 of the 12 factors compared between the two stocks.

About Leap Therapeutics

Leap Therapeutics, Inc., a biopharmaceutical company, acquires and develops therapies for the treatment of cancer. Its lead clinical stage programs include DKN-01, a monoclonal antibody that inhibits Dickkopf-related protein 1, which is in multiple ongoing clinical trials for treating esophagogastric, hepatobiliary, gynecologic, and prostate cancers. Leap Therapeutics, Inc. has an option and license agreement with BeiGene, Ltd. to develop and commercialize DKN-01 in Asia (excluding Japan), Australia, and New Zealand. The company was formerly known as HealthCare Pharmaceuticals, Inc. and changed its name to Leap Therapeutics, Inc. in November 2015. Leap Therapeutics, Inc. was incorporated in 2011 and is based in Cambridge, Massachusetts.

About Actinium Pharmaceuticals

Actinium Pharmaceuticals, Inc. develops antibody radiation conjugates and other targeted radiotherapies intended to improve outcomes for people who have failed existing oncology therapies. Its Iomab-B is an induction and conditioning agent prior to bone marrow transplant in patients with relapsed and refractory acute myeloid leukemia (r/r AML). The company focuses on advancing its development for product candidate Actimab-A, a therapeutic agent that has demonstrated potential activity in r/r AML patients. In addition, it engages with the National Cancer Institute under the cooperative research and development agreement for the development of Actimab-A in AML and other myeloid malignancies. Its Iomab-ACT, a next generation conditioning candidate, is being developed for improving patient access and outcomes for curative cell and gene therapies. Further, the company’s research and development activities primarily focus on advancing various preclinical programs for solid tumor indications. The company holds approximately 235 patents and patent applications, including various patents related to the manufacture of the isotope Ac-225 in a cyclotron. The company is based in New York, New York.